Written by
Mustafa Çelik
Mustafa Çelik Liv Hospital Content Team
Medically reviewed by

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Prof. MD. Yasemin Altuner Torun Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
...
Views
Read Time
...
views
Read Time
SEP 15314 image 1 LIV Hospital
Can You Die From Skin Cancer? Scary Realities 4

Squamous cell carcinoma (SCC) is a serious skin cancer that can be deadly if not treated quickly. Early treatment leads to high survival rates. But, advanced disease is a big worry.

The Global Burden of Disease Study 2021 found 169,820 cases of pharyngeal cancer. Sadly, 98,435 people died from it.

Death from SCC often comes from advanced disease. This includes metastasis to lymph nodes and distant organs. It also includes invasion of important local structures and complications like infection, bleeding, and organ failure.

Understanding these causes is key to improving survival rates. It helps in providing top-notch, lifesaving care.

Key Takeaways

  • SCC is a serious form of skin cancer with significant mortality rates.
  • Advanced disease is a major contributor to skin cancer mortality.
  • Metastasis and local invasion are primary causes of fatal outcomes.
  • Complications such as infection and organ failure can be life-threatening.
  • Early treatment is critical for improving survival rates.

Understanding Squamous Cell Carcinoma

SEP 15314 image 2 LIV Hospital
Can You Die From Skin Cancer? Scary Realities 5

Squamous cell carcinoma is a common skin cancer. It comes from squamous cells in the skin’s outer layer. This cancer is serious because it can spread if not treated quickly.

Definition and Types of SCC

Squamous cell carcinoma is a cancer of the squamous cells in the skin’s outer layer. There are two main types: keratinizing SCC and non-keratinizing SCC. The keratinizing type is more common.

The keratinizing type makes keratin, a protein in skin, hair, and nails. Knowing these types helps doctors plan the best treatment.

Prevalence and Incidence Rates

Squamous cell carcinoma is a common skin cancer. It affects many people and is getting more common. This is mainly because of more sun exposure or tanning bed use.

Type of SCC

Five-Year Survival Rate

Characteristics

Early-Stage SCC

99%

Localized, small tumors

Metastatic SCC

<50%

Spread to lymph nodes or distant organs

The table shows why catching SCC early is key. Early-stage SCC has a 99% survival rate. But, metastatic SCC’s rate is below 50%. This shows the importance of quick diagnosis and treatment.

Knowing how common SCC is helps doctors and patients. It guides screening and treatment plans. This affects the skin cancer prognosis for those with SCC.

The Natural Progression of Squamous Cell Carcinoma

SEP 15314 image 3 LIV Hospital
Can You Die From Skin Cancer? Scary Realities 6

SCC can grow from small lesions to big tumors that are very dangerous. Knowing how SCC grows helps doctors catch it early. This can save lives. We will look at how SCC grows and what makes it spread.

Early Stage Development

SCC starts as small, rough spots on the skin. These spots might not hurt but can bleed or hurt as they get bigger. It’s very important to find SCC early because it’s easier to treat then.

Advanced Stage Characteristics

As SCC gets worse, it can spread to deeper parts of the body. This can cause a lot of harm and even death. SCC is more likely to spread than some other skin cancers. So, acting fast is key.

Experts say,

“The mortality rate for SCC can be significant if the disease is not managed promptly and effectively.”

This shows why we need to understand how SCC grows. It helps doctors do better for their patients.

Can You Die From Skin Cancer? The Reality of SCC Mortality

It’s important to look at the facts about dying from skin cancer, like SCC. Squamous Cell Carcinoma is a serious skin cancer. It can spread and cause a lot of harm and death.

Mortality Statistics and Trends

In 2021, SCC caused a lot of deaths. The death rates varied by region. Things like where you live, healthcare access, and UV exposure play a big role.

Key statistics on SCC mortality include:

  • Age-standardized mortality rates range from 0.5 to 2 per 100,000 population in various regions.
  • SCC accounts for a significant proportion of skin cancer-related deaths.
  • Mortality rates are higher in older populations and among individuals with immunosuppression.

Comparison to Other Skin Cancers

SCC is compared to other skin cancers like Basal Cell Carcinoma (BCC) and Melanoma. SCC’s death rate is lower than melanoma but more common. BCC is less aggressive than SCC.

The comparison highlights the following:

  1. SCC has a higher mortality rate than BCC due to its ability to spread.
  2. Melanoma, though less common, has a higher death rate per case than SCC.
  3. The overall death toll from SCC is big because it’s more common than melanoma.

It’s key to understand these facts to fight SCC deaths. Finding and treating SCC early can save lives.

Primary Causes of Death in SCC Patients

It’s key to know why SCC patients die to make treatments better. We must look at what leads to death to help more people survive.

Metastasis to Lymph Nodes

When SCC spreads to lymph nodes, it’s a big problem. This means the disease is more advanced, making treatment harder. The lymph nodes make surgery tougher and treatment more aggressive, like using radiation and chemotherapy.

Cancer cells move from the main tumor to the lymph nodes. This can happen directly or through lymphatic vessels. Once in the lymph nodes, they can grow and spread to other parts of the body.

Distant Organ Involvement

When SCC reaches distant organs like the lungs, liver, or bones, it’s very serious. This stage is hard to treat and often leads to death. It shows the disease has spread beyond the lymph nodes, making it hard to control.

Handling SCC that has spread to distant organs needs a team effort. This includes using chemotherapy, targeted therapy, and immunotherapy. Even with these treatments, the outlook is often not good. This shows we need to catch and treat SCC early to stop it from getting this far.

We know it’s vital for doctors and researchers to understand these causes of death in SCC patients. By stopping metastasis and finding better treatments for advanced disease, we can lower SCC mortality rates.

Critical Local Structure Invasion

Squamous cell carcinoma (SCC) can invade critical local structures, leading to severe and potentially fatal outcomes. When SCC invades vital areas, it can cause significant damage. This makes treatment efforts complicated.

Brain Invasion and Complications

Brain invasion is a severe complication of SCC. It can cause neurological deficits, seizures, and even death. The prognosis for patients with brain metastasis is generally poor, with limited treatment options available.

Common complications of brain invasion include:

  • Cognitive impairment
  • Motor function loss
  • Seizures
  • Personality changes

Bone and Deep Soft Tissue Involvement

Involvement of bone and deep soft tissues by SCC can lead to significant morbidity. Bone invasion can cause pain, fractures, and limited mobility. Deep soft tissue involvement can result in extensive tissue damage and functional impairment.

The impact of bone and deep soft tissue involvement on patient outcomes can be substantial. Treatment often requires a multidisciplinary approach. This includes surgery, radiation therapy, and palliative care to manage symptoms and improve quality of life.

Structure Involved

Common Complications

Impact on Prognosis

Brain

Neurological deficits, seizures

Poor, with limited treatment options

Bone

Pain, fractures, limited mobility

Significant morbidity, complex treatment

Deep Soft Tissues

Extensive tissue damage, functional impairment

Substantial impact on quality of life

Understanding the consequences of critical local structure invasion by SCC is key. It’s important for developing effective treatment strategies and improving patient outcomes. Early detection and intervention are critical to preventing these severe complications.

Secondary Complications Leading to Mortality

Squamous cell carcinoma (SCC) can lead to serious complications that affect survival rates. Understanding these complications is key to giving patients the best care.

Infection and Sepsis

Infections are a big worry for SCC patients, mainly those with advanced disease. The risk of sepsis, a dangerous body reaction to infection, is higher. Sepsis can cause organ failure if not treated quickly.

We must watch for infection signs and start antibiotics when needed. Infections can come from the tumor, surgery sites, or other weak spots. Good wound care and infection control are vital to prevent these issues.

Hemorrhage and Bleeding Complications

Bleeding is a big worry for SCC patients, more so for those with tumors in key areas. Bleeding can be sudden or ongoing, and severe cases can be deadly. Handling bleeding complications needs a team effort, including surgery, radiation, and support care.

SCC tumors can sometimes break into big blood vessels, causing severe bleeding. Quick action to manage these events is essential to avoid fatal outcomes. Knowing the risks of SCC and its treatments helps healthcare teams prepare for and manage these serious problems.

As we learn more about SCC, it’s clear that secondary complications greatly affect patient outcomes. By tackling these complications early, we can lower the death rate from skin cancer.

Organ Failure as a Terminal Event

Organ failure is a serious and often fatal issue in advanced squamous cell carcinoma. As SCC gets worse, it can cause vital organs to fail. This greatly affects patient outcomes. We will look at how organ failure, like respiratory failure and multiple organ dysfunction syndrome, impacts SCC mortality.

Respiratory Failure

Respiratory failure is a major cause of death in SCC patients. This happens when the cancer spreads to the lungs or invades the airways. Respiratory failure can be caused by:

  • Tumor blocking the airways
  • Pneumonia or infections making the disease worse
  • Pulmonary metastases

When respiratory failure happens, it usually means the cancer has reached a critical point. It shows the cancer has severely harmed the patient’s breathing and oxygen levels.

Multiple Organ Dysfunction Syndrome

Multiple organ dysfunction syndrome (MODS) is another serious condition in advanced SCC patients. MODS happens when two or more organs fail to meet the body’s needs. This syndrome can be caused by:

  1. Severe infections or sepsis
  2. Cancer spreading and growing
  3. Complications from treatment

MODS has high mortality rates because it shows a failure of the body’s key systems. Treating MODS is hard and often needs intensive care.

In summary, organ failure, including respiratory failure and multiple organ dysfunction syndrome, is a big factor in SCC mortality. Knowing about these complications is key to better patient care and outcomes.

Skin Cancer Survival Rates and Prognosis Factors

Skin cancer survival rates are much higher when caught early. Knowing the survival rates and what affects them is key for patients and doctors. This info helps in choosing the best treatment and managing the disease.

Early vs. Late Stage Survival Statistics

The survival rate for skin cancer changes a lot based on when it’s found. Early-stage squamous cell carcinoma (SCC) has a much better survival rate than late-stage. Studies show that the 5-year survival rate for early SCC is over 90%. But, for late-stage disease, it’s much lower.

Here are some key survival statistics:

  • Localized SCC: 90% or higher 5-year survival rate
  • Regional SCC (spread to nearby lymph nodes): 50-70% 5-year survival rate
  • Distant SCC (spread to distant organs): 20-30% 5-year survival rate

Factors Influencing Skin Cancer Prognosis

Many things can affect how well a skin cancer patient will do. These include:

  1. Tumor Characteristics: The size, thickness, and location of the tumor matter. So does whether it has ulceration.
  2. Patient Health: Your overall health, immune status, and any other health issues are important.
  3. Genetic Factors: Some genetic mutations can make the cancer more aggressive or harder to treat.

Early detection and timely intervention are key to better survival rates. Regular check-ups and a team approach to care can greatly improve outcomes.

We stress the need for awareness and education on skin cancer risks and prevention. By knowing what affects skin cancer prognosis, patients can take steps for early detection and effective management.

High-Risk Populations for SCC Mortality

It’s important to know who is most at risk for squamous cell carcinoma (SCC) mortality. Some groups face a higher risk due to different reasons.

Elderly Patients

Elderly people are more likely to die from SCC. As we age, our immune system gets weaker. This makes it harder for our bodies to fight cancer.

Older adults might also have other health problems. These can make treating SCC even harder.

Key factors contributing to increased risk in elderly patients include:

  • Decreased immune function
  • Presence of comorbidities
  • Delayed diagnosis due to less frequent medical check-ups

Immunocompromised Individuals

People with weakened immune systems, like those with HIV/AIDS or organ transplant recipients, are also at higher risk. Their bodies struggle to control SCC.

The increased risk in immunocompromised individuals can be attributed to:

  • Suppressed immune response
  • Increased susceptibility to SCC development and progression
  • Potential for more aggressive SCC behavior

We need to focus on these high-risk groups when planning SCC prevention and treatment. Early detection and personalized plans can greatly improve their outcomes.

Population

Risk Factors

Potential Interventions

Elderly Patients

Decreased immune function, comorbidities, delayed diagnosis

Regular skin checks, timely SCC diagnosis, personalized treatment plans

Immunocompromised Individuals

Suppressed immune response, increased SCC susceptibility, aggressive SCC behavior

Close monitoring for SCC development, aggressive management of SCC, adjustment of immunosuppressive therapy when possible

Global Trends in SCC Mortality

It’s key to know the global trends in SCC mortality to fight this deadly skin cancer. We’ll look at how death rates have changed over time and in different groups and places.

Historical Patterns (1990-2021)

In the last 30 years, SCC death rates have changed a lot. A study on PubMed shows an increase in SCC cases and deaths in some groups. Here’s what we found:

  • Death rates from SCC have gone up, mainly in older people.
  • Death rates vary a lot by place, with more deaths in sunny areas.
  • Better ways to find and report SCC have helped show these trends.

Geographic and Demographic Variations

SCC death rates differ a lot by place and who gets it. We’ve seen that:

  1. Places with more sun have more SCC cases and deaths.
  2. Older folks and those with weak immune systems face higher risks.
  3. Men tend to have more SCC deaths than women.

This shows we need to focus our health efforts and spread the word to lower SCC deaths everywhere.

By grasping these global trends, we can plan better and fight fatal skin cancer more effectively.

The Critical Importance of Early Detection

Early detection is key to managing squamous cell carcinoma well. Finding skin cancer early is essential for better skin cancer survival rates and patient results.

Early detection is very important. Finding SCC early means treatments work better, and the outlook is much better. This is because early SCC is easier to treat.

Screening Recommendations

Regular skin checks are vital for catching SCC early. We suggest that people, mainly those at high risk, get regular checks from a dermatologist. These checks should cover all skin, including sun-exposed areas.

  • Annual skin exams for high-risk individuals
  • Monthly self-exams to spot new or changing spots
  • Knowing about risk factors, like too much sun and being immunosuppressed

The table below shows when to get screened based on risk:

Risk Category

Recommended Screening Frequency

Low Risk

Every 2-3 years

Moderate Risk

Annually

High Risk

Every 6 months

Warning Signs and Symptoms

Knowing the signs and symptoms of SCC is key for early detection. We tell people to look out for:

  • Persistent, non-healing sores or ulcers
  • New or changing growths on the skin
  • Red, scaly patches or firm nodules

By knowing these signs, people can get medical help fast. This improves their skin cancer prognosis. Early detection and treatment are essential for managing SCC well and lowering death rates from this disease.

Treatment Challenges and Their Impact on Fatal Skin Cancer

SCC treatment faces many hurdles, like resistance to common treatments and disease that keeps coming back. These issues can raise the risk of death from skin cancer. To better manage SCC, we need to grasp these challenges and find ways to improve patient care.

Resistance to Standard Therapies

One big problem in SCC treatment is when tumors stop responding to usual treatments. This makes it hard to stop the disease from getting worse. Genetic changes, different types of cancer cells, and the environment around the tumor all play a role in this resistance.

  • Genetic changes that make drugs less effective or find new ways to grow.
  • Different types of cancer cells that might not be affected by treatment.
  • The environment around the tumor that can shield cancer cells from drugs.

Management of Recurrent Disease

When SCC comes back, it’s often a sign of a more serious disease. Handling this situation needs a team effort, using different treatments based on each patient’s needs. The right treatment depends on where and how much the disease has come back, and the patient’s overall health.

  1. Checking the tumor to see if it has changed in any way.
  2. Looking into other treatments, like targeted therapy or immunotherapy.
  3. Using palliative care to help patients with advanced disease live better.

By tackling these treatment challenges, we can lower the risk of fatal skin cancer in SCC patients. It’s vital to keep researching and finding new ways to fight resistance and manage disease that keeps coming back.

Advanced Treatment Approaches to Reduce Skin Cancer Fatality

We are seeing big changes in how we treat SCC. New care models and therapies are making a big difference. This is helping more people survive skin cancer.

Multidisciplinary Care Models

Now, treating SCC involves a team effort. Experts from dermatology, surgery, and more work together. This ensures each patient gets care that fits their needs.

This team approach means using different treatments like surgery and radiotherapy. It helps find the best way to help each patient. And it allows for changes in treatment if needed.

Innovative Therapies and Clinical Trials

New treatments like targeted and immunotherapies are changing SCC care. They show great promise in helping patients and reducing death rates.

Clinical trials are key in finding new SCC treatments. They let patients try new therapies not yet available. We’re working hard to bring new treatments to SCC patients.

The mix of team care and new therapies is changing SCC treatment. We’re excited about the future. We’re hopeful we can keep improving patient outcomes.

Conclusion: The Future of SCC Management and Mortality Reduction

Understanding the risks of squamous cell carcinoma is key in the fight against skin cancer deaths. The question “can you die from skin cancer” is a harsh reality for many. It’s a concern for those diagnosed with advanced SCC.

Early detection and advanced care are vital in lowering SCC death rates. By spotting high-risk groups and pushing for screenings, we can boost survival rates. This helps cut down on fatal cases.

New treatments and clinical trials bring hope to SCC patients. A team approach, with dermatologists, surgeons, and oncologists, offers complete care. This ensures the disease is managed well.

As we progress, it’s critical to keep researching SCC causes of death. We must also find ways to lower skin cancer mortality. By joining forces, we can better patient outcomes and lessen SCC’s global impact.

FAQ

Can you die from skin cancer?

Yes, skin cancer, like squamous cell carcinoma (SCC), can be deadly if not caught early. We’ll look at why SCC can be fatal, including when it spreads and invades important areas.

What are the primary causes of death in SCC patients?

SCC patients often die from spreading to lymph nodes and distant organs. They can also die from invading critical areas and facing complications like infections and organ failure.

How does SCC progress?

SCC starts small but can grow and spread. It can invade important areas and spread to other parts of the body. This can lead to serious problems and even death.

What are the mortality statistics and trends for SCC?

SCC deaths affect many people, with different trends in different places. Knowing these trends helps us create better health strategies.

How does SCC compare to other skin cancers in terms of mortality?

SCC is more deadly than some other skin cancers, mainly when it spreads or invades important areas. We compare SCC to other cancers to understand its impact.

What are the high-risk populations for SCC mortality?

Older people and those with weakened immune systems are at higher risk for SCC death. They need special care to lower their risk of fatal outcomes.

What is the survival rate for SCC?

SCC survival rates depend on when it’s found. Early-stage SCC has a better chance of survival than late-stage. Knowing survival rates helps in caring for patients.

What are the treatment challenges for SCC?

Treating SCC can be tough, like when it doesn’t respond to usual treatments or comes back. New treatments and team care are needed to improve outcomes.

How can SCC mortality be reduced?

Lowering SCC death rates means finding it early, using advanced care, and trying new treatments. We stress the need for screenings and knowing the signs and symptoms.

What is the role of organ failure in SCC mortality?

Organ failure, like breathing problems or failing multiple organs, is a major cause of death in SCC patients. It often comes from the cancer spreading, invading important areas, and causing secondary issues.

What are the global trends in SCC mortality?

SCC death rates have shown patterns and differences around the world. This highlights the need for global health strategies and targeted efforts to cut down SCC deaths worldwide.

References

PubMed / NCBI — Global, regional, national prevalence, mortality, and disability-adjusted life-years of cutaneous squamous cell carcinoma and trend analysis from 1990 to 2021 and prediction to 2045
https://pubmed.ncbi.nlm.nih.gov/39980558/

i

Medical Disclaimer

The content on this page is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider regarding any medical conditions.

Book a Free Certified Online
Doctor Consultation

Clinics/branches
GDPR

We're Here to Help.
Get in Touch

Send us all your questions or requests, and our
expert team will assist you.

Our Doctors

Assoc. Prof. MD. Evrim Duman Radiation Oncology

Assoc. Prof. MD. Evrim Duman

Liv Hospital Ulus
Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology

Asst. Prof. MD. Meltem Topalgökçeli Selam

Liv Hospital Ulus
Prof. MD. Duygu Derin Medical Oncology

Prof. MD. Duygu Derin

Liv Hospital Ulus
Prof. MD. Emre Merdan Fayda Radiation Oncology

Prof. MD. Emre Merdan Fayda

Liv Hospital Ulus
Prof. MD. Mehmet Hilmi Doğu Hematology

Prof. MD. Mehmet Hilmi Doğu

Liv Hospital Ulus
Liv Hospital Bahçeşehir
Prof. MD. Meral Günaldı Medical Oncology

Prof. MD. Meral Günaldı

Liv Hospital Ulus
Assoc. Prof. MD. Murat Ayhan Medical Oncology

Assoc. Prof. MD. Murat Ayhan

Liv Hospital Vadistanbul
Prof. MD.  Itır Şirinoğlu Demiriz Hematology

Prof. MD. Itır Şirinoğlu Demiriz

Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology

Prof. MD. Tülin Tıraje Celkan

Liv Hospital Vadistanbul
Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology

Assoc. Prof. MD. Erkan Kayıkçıoğlu

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Mine Dağgez Gynecological Oncology

Assoc. Prof. MD. Mine Dağgez

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Ozan Balakan Medical Oncology

Assoc. Prof. MD. Ozan Balakan

Liv Hospital Bahçeşehir
MD. Taylan Bükülmez Radiation Oncology

MD. Taylan Bükülmez

Liv Hospital Bahçeşehir
Op. MD. Alp Koray Kinter Gynecological Oncology

Op. MD. Alp Koray Kinter

Liv Hospital Bahçeşehir
Prof. MD. Nuri Faruk Aykan Medical Oncology

Prof. MD. Nuri Faruk Aykan

Liv Hospital Bahçeşehir
Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology

Prof. MD. Yasemin Altuner Torun

Liv Hospital Bahçeşehir
Spec. MD. Özlem Doğan Medical Oncology

Spec. MD. Özlem Doğan

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Emir Çelik Medical Oncology

Assoc. Prof. MD. Emir Çelik

Liv Hospital Topkapı
Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology

Assoc. Prof. MD. Muhammed Mustafa Atcı

Liv Hospital Topkapı
Prof. MD. İrfan Çiçin Medical Oncology

Prof. MD. İrfan Çiçin

Liv Hospital Topkapı
Assoc. Prof. MD.  Ramazan Öcal Hematology

Assoc. Prof. MD. Ramazan Öcal

Liv Hospital Ankara
Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology

Assoc. Prof. MD. Nazlı Topfedaisi Özkan

Liv Hospital Ankara
Prof. MD. Fikret Arpacı Medical Oncology

Prof. MD. Fikret Arpacı

Liv Hospital Ankara
Prof. MD. Gökhan Erdem Medical Oncology

Prof. MD. Gökhan Erdem

Liv Hospital Ankara
Prof. MD. Meral Beksaç Hematology

Prof. MD. Meral Beksaç

Liv Hospital Ankara
Prof. MD. Oral Nevruz Hematology

Prof. MD. Oral Nevruz

Liv Hospital Ankara
Prof. MD. Saadettin Kılıçkap Medical Oncology

Prof. MD. Saadettin Kılıçkap

Liv Hospital Ankara
Prof. MD. Sadık Muallaoğlu Medical Oncology

Prof. MD. Sadık Muallaoğlu

Liv Hospital Ankara
Spec. MD. Ender Kalacı Medical Oncology

Spec. MD. Ender Kalacı

Liv Hospital Ankara
Assoc. Prof. MD. Fadime Ersoy Dursun Hematology

Assoc. Prof. MD. Fadime Ersoy Dursun

Liv Hospital Gaziantep
Prof. MD. Fatih Teker Medical Oncology

Prof. MD. Fatih Teker

Liv Hospital Gaziantep
Spec. MD. ELXAN MEMMEDOV Medical Oncology

Spec. MD. ELXAN MEMMEDOV

Liv Bona Dea Hospital Bakü
Spec. MD. Ceyda Aslan Hematology

Spec. MD. Ceyda Aslan

Spec. MD. Elkhan Mammadov Medical Oncology

Spec. MD. Elkhan Mammadov

Spec. MD. Elmir İsrafilov Hematology

Spec. MD. Elmir İsrafilov

Spec. MD. Minure Abışova Eliyeva Hematology

Spec. MD. Minure Abışova Eliyeva

Spec. MD. Natavan Azizova Medical Oncology

Spec. MD. Natavan Azizova

Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 174 42 01